Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 10/20 | 0.36 |
| ▸ | CNR2 | P34972 | 8/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4699553 | 0.89 | PDK1 (0.41) | CNR1CNR2PDK1PDK2PDK3 | |
| SCHEMBL4699146 | 0.87 | KIF11 (0.41) | KIF11PDK1PDK2PDK3PDK4 | |
| SCHEMBL1111305 | 0.72 | PDK1 (0.45) | KIF11PDK1PDK2PDK3PDK4 | |
| SCHEMBL4698291 | 0.70 | BACE1 (0.35) | CYP3A4 | |
| SCHEMBL22302828 | 0.70 | PTPN5 (0.44) | KIF11PDK1PDK2PDK3PDK4 | |
| SCHEMBL28831875 | 0.69 | GLA (0.44) | CNR1CNR2PDK1PDK2PDK3 | |
| SCHEMBL30876217 | 0.69 | ENPP2 (0.44) | CNR1CNR2GSK3B | |
| SCHEMBL179266 | 0.69 | KIF11 (0.50) | KIF11PDK1PDK2PDK3PDK4 | |
| SCHEMBL29421430 | 0.69 | KIF11 (0.50) | KIF11PTPN5GRM5VNN1MRGPRX4 | |
| SCHEMBL440276 | 0.69 | KIF11 (0.50) | KIF11PTPN5GRM5VNN1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937638-A1 | METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-2007047306-A1 | METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | APP, DNPEP, ASPH | KIF11 4550/4885CNR1 4555/4885CNR2 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.